Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B
2010-023072-17Phase 3
- Sponsor
- Novo Nordisk
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Incidence of inhibitory antibodies against factor IX.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2010-023072-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023072-17.